📰 Dan Caley News
Page 2 - Dan Caley News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Dan Caley. Real-time updates on events, politics, business and more.
September 28, 2022
/PRNewswire/ -- Pharming Group N.V. ("Pharming" or "the Company") (Euronext Amsterdam: PHARM) (NASDAQ: PHAR) announces that the US Food and Drug Administration...
September 28, 2022
The FDA has assigned a PDUFA goal date of March 29, 2023 for the NDA submission based on randomized-controlled and long-term extension data for leniolisib as a treatment for APDS, a rare primary
September 26, 2022
LISBON, Portugal, Sept. 26, 2022 (GLOBE NEWSWIRE) -- SOMAÍ Pharmaceuticals Unipessoal LDA has officially opened its new state-of-the-art pharmaceutical...
April 26, 2022
An agreed Paediatric Investigation Plan (PIP) is the regulatory pathway to market authorization for leniolisib as a treatment for activated phosphoinositide 3-kinase delta syndrome (APDS) in
April 26, 2022
Press release content from PR Newswire. The AP news staff was not involved in its creation.
April 26, 2022
/PRNewswire/ -- Pharming Group N.V. ("Pharming" or the "Company") (EURONEXT Amsterdam: PHARM/Nasdaq: PHAR) announces that it has received a positive decision...
April 26, 2022
/PRNewswire/ -- Pharming Group N.V. ("Pharming" or the "Company") (EURONEXT Amsterdam: PHARM) (Nasdaq: PHAR) announces that it has received a positive decision...
April 26, 2022
/PRNewswire/ -- Pharming Group N.V. ("Pharming" or the "Company") (EURONEXT Amsterdam: PHARM) (Nasdaq: PHAR) announces that it has received a positive decision...
April 1, 2022
/PRNewswire/ -- Pharming Group N.V. ("Pharming" or "the Company") (EURONEXT Amsterdam: PHARM/Nasdaq: PHAR) announces new data from the pivotal Phase II/III...
April 1, 2022
LEIDEN, Netherlands, April 1, 2022 /PRNewswire/ -- Pharming Group N.V. ("Pharming" or "the Company") (EURONEXT Amsterdam: PHARM/Nasdaq: PHAR) announces new data from the pivotal Phase II/III